Nuclease-Mediated BCL11A Enhancer Editing for Hemoglobinopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating hemoglobinopathies such as sickle cell disease and beta thalassemia are inadequate, with treatments like hydroxyurea having long-term side effects and variable efficacy, and bone marrow transplants carrying significant risks, while existing gene therapy approaches face challenges in completely knocking down BCL11A expression and delivering inhibitory RNAs effectively.
Innovation Solution
The development of genetically modified cells using nucleases like zinc finger nucleases, TALENs, or CRISPR/Cas systems to target and modify the BCL11A gene, specifically interfering with its enhancer functions to down-regulate its activity, thereby increasing gamma globin expression, which can help treat hemoglobinopathies by altering BCL11A gene expression in hematopoietic stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to treat hemoglobinopathies, then gamma globin expression is increased, but long-term side effects and variable efficacy occur
Solution Approach 1:
The patent extracts and targets the specific regulatory mechanism (BCL11A enhancer) that controls gamma-globin repression, removing the need for pharmacological agents like hydroxyurea. By using nucleases to precisely disrupt the enhancer region, the treatment directly addresses the molecular cause of gamma-globin suppression without the side effects of chemical therapy.
Solution Approach 2:
The patent introduces nucleases (ZFNs, TALENs, or CRISPR/Cas systems) as intermediary tools to mediate the desired genetic modification. These nucleases serve as precise molecular intermediaries that target and disrupt the BCL11A enhancer, enabling controlled gamma-globin reactivation without direct exposure to toxic chemicals.
2Reliability
If bone marrow transplant is performed to treat hemoglobinopathies, then curative outcomes are achieved, but significant risks are incurred
Solution Approach 1:
The patent enables the patient's own hematopoietic stem cells to be modified ex vivo and then retransferred autologously. This self-service approach eliminates the need for allogeneic donors and associated immune rejection risks, while achieving curative outcomes through precise genetic modification of the patient's own cells.
Solution Approach 2:
The patent replaces the mechanical/surgical complexity of bone marrow transplantation with a molecular-level genetic modification approach. Instead of transplanting entire organ systems, the treatment uses nucleases to precisely edit specific DNA sequences, substituting a molecular mechanism for a surgical procedure.
3Reliability
If inhibitory RNA is used to knock down BCL11A expression, then gamma globin expression increases, but delivery challenges and incomplete knockdown occur
Solution Approach 1:
The patent extracts and targets the specific functional element (enhancer region) responsible for BCL11A's repressive activity. By using nucleases to disrupt this enhancer directly, the treatment achieves more complete and reliable knockdown of BCL11A function compared to RNA interference, while eliminating the need for complex delivery mechanisms required for RNA therapeutics.
Solution Approach 2:
The patent uses nucleases that can be delivered as DNA sequences encoding the nuclease proteins, which then replicate and express the nuclease activity within the target cells. This copying mechanism allows for sustained expression and activity without requiring continuous delivery of RNA therapeutics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to increased expression of gamma globin, potentially reducing the severity of hemoglobinopathies by modifying BCL11A gene activity in specific cell lineages, offering a more effective and sustainable treatment option compared to existing therapies.
Implementation Method 1
This approach leads to increased expression of gamma globin, potentially reducing the severity of hemoglobinopathies by modifying BCL11A gene activity in specific cell lineages
Data Source
AI summary
The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.